A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer

New England Journal of Medicine

Volumn 355, Issue 6, 2006, Pages 570-580

  Potti, Anil ^a,b   Mukherjee, Sayan ^a   Petersen, Rebecca ^b   Dressman, Holly K ^a,b   Bild, Andrea ^a,b   Koontz, Jason ^a,b   Kratzke, Robert ^c   Watson, Mark A ^d   Kelley, Michael ^b   Ginsburg, Geoffrey S ^a,b   West, Mike ^a   Harpole Jr , David H ^b   Nevins, Joseph R ^a,b  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER MODEL; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CHEMOTHERAPY; CONTROLLED STUDY; DECISION MAKING; FEMALE; GENE EXPRESSION; GENOME ANALYSIS; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MODELS, GENETIC; MULTIGENE FAMILY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RISK; RNA, NEOPLASM; SURVIVAL ANALYSIS;

EID: 33746875641     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa060467     Document Type: Article

References (31)

1. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379-92.
2. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000;355:479-85. [Erratum, Lancet 2000;355:1280.]
3. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-7.
4. Nesbitt JC, Putnam JB Jr, Walsh GL, Roth JA, Mountain CF. Survival in early-stage non-small cell lung cancer. Ann Thorac Surg 1995;60:466-72.
5. Mountain CF. The new International Staging System for Lung Cancer. Surg Clin North Am 1987;67:925-35.
6. D'Amico TA, Massey M, Herndon JE II, Moore MB, Harpole DH Jr. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 1999;117:736-43.
7. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002;122:1037-57.
8. Meyerson M, Carbone DP. Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. J Clin Oncol 2005;23:3219-26.
9. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60.
10. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97.
11. Douillard J-Y, Rosell R, Delena M, Legroumellec A, Torres A, Carpagnano F. ANITA: phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): final results after 70-month median follow-up. J Clin Oncol 2005;23:Suppl:7013. abstract.
12. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004;350:1713-21.
13. Strauss GM. Herndon JE II, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage 1B non-small cell lung cancer. J Clin Oncol 2004;22:7019. abstract.
14. Tonon G, Wong KK, Maulik G, et al. High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A 2005;102:9625-30.
15. Schneider PM, Praeuer HW, Stoeltzing O, et al. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer. Br J Cancer 2000;83:473-9.
16. Berrar D, Sturgeon B, Bradbury I, Downes CS, Dubitzky W. Survival trees for analyzing clinical outcome in lung adenocarcinomas based on gene expression profiles: identification of neogenin and diacylglycerol kinase alpha expression as critical factors. J Comput Biol 2005;12:534-44.
17. Ju Z, Kapoor M, Newton K, et al. Global detection of molecular changes reveals concurrent alteration of several biological pathways in nonsmall cell lung cancer cells. Mol Genet Genomics 2005;274:141-54.
18. Beer DG, Kardia SLR, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-24.
19. Chen G, Gharib TG, Wang H, et al. Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci U S A 2003;100:13537-42.
20. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001;98:13790-5.
21. Wigle DA, Jurisica I, Radulovich N, et al. Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res 2002;62:3005-8.
22. Kikuchi T, Daigo Y, Katagiri T, et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 2003;22:2192-205.
23. Garber ME, Troyanskaya OG, Schluens K, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A 2001;98:13784-9.
24. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-98.
25. Pittman J, Huang E, Dressman H, et al. Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci U S A 2004;101:8431-6.
26. Pittman J, Huang E, Nevins JR, Wang Q, West M. Bayesian analysis of binary prediction tree models for retrospectively sampled outcomes. Biostatistics 2004;5:587-601.
27. Nevins JR, Huang ES, Dressman H, Pittman J, Huang AT, West M. Towards integrated clinico-genomic models for personalized medicine: combining gene expression signatures and clinical factors in breast cancer outcomes prediction. Hum Mol Genet 2003;12:R153-R157.
28. Huang E, Cheng SH, Dressman H, et al. Gene expression predictors of breast cancer outcomes. Lancet 2003;361:1590-6.
29. West M, Blanchette C, Dressman H, et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A 2001;98:11462-7.
30. Denison DGT, Mallick BK, Smith AFM. A Bayesian CART algorithm. Biometrika 1998;85:363-77.
31. Breiman L. Statistical modeling: the two cultures. Stat Sci 2001;16:199-225.